Integrating Immunotherapy Into Colorectal Cancer Care
Until recent studies were reported, immunotherapy was thought to be ineffective for colorectal cancer; this article provides guidance on how to incorporate immunotherapy into this setting.
Mismatch Repair-Deficient Colorectal Tumors Responded to Pembrolizumab
In this video, Dung T. Le, MD, discusses a phase II study that found that mismatch repair–deficient colorectal tumors were highly responsive to checkpoint blockade with the anti–PD-1 drug pembrolizumab.